NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $1.15 -0.25 (-17.86%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.20 +0.06 (+4.78%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Acrivon Therapeutics Stock (NASDAQ:ACRV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acrivon Therapeutics alerts:Sign Up Key Stats Today's Range$0.97▼$1.4050-Day Range$1.15▼$2.1552-Week Range$0.97▼$3.56Volume1.29 million shsAverage Volume197,944 shsMarket Capitalization$49.28 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company Overview Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors. Founded in 2018 and headquartered in Watertown, Massachusetts, Acrivon conducts drug development and clinical research. The company was co-founded by Peter Blume-Jensen, M.D., Ph.D., who serves as its chief executive officer.AI Generated. May Contain Errors. Read More Acrivon Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreACRV MarketRank™: 3.09009009009 of 5 starsAcrivon Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 211th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAcrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAcrivon Therapeutics has a consensus price target of $13.50, representing about 1,073.9% upside from its current price of $1.15.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acrivon Therapeutics are expected to grow in the coming year, from ($1.69) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.71% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 11.37, which indicates bearish sentiment.Change versus previous monthShort interest in Acrivon Therapeutics has recently increased by 3.85%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.06 News SentimentAcrivon Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Acrivon Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,320.00 in company stock.Percentage Held by Insiders10.50% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRV Stock News HeadlinesWall Street Zen Upgrades Acrivon Therapeutics (NASDAQ:ACRV) to HoldNovember 21 at 1:12 AM | americanbankingnews.comAcrivon Reports Phase 1/2 ACR-2316 Dose-Escalation ResultsNovember 20 at 4:51 PM | tipranks.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 21 at 1:00 AM | Weiss Ratings (Ad)Acrivon Therapeutics (NASDAQ:ACRV) Earns Market Outperform Rating from Citizens JmpNovember 19 at 1:24 AM | americanbankingnews.comAcrivon Reports Third Quarter 2026 Financial Results and Business HighlightsNovember 16, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Acrivon Therapeutics, Inc. (ACRV)November 12, 2026 | theglobeandmail.comAcrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program TranscriptNovember 10, 2026 | seekingalpha.comAcrivon Therapeutics Hosts Webcast Introducing New Immunology ProgramsNovember 10, 2026 | tipranks.comSee More Headlines ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $2.41 at the beginning of the year. Since then, ACRV stock has decreased by 52.3% and is now trading at $1.15. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its earnings results on Monday, November, 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. Who are Acrivon Therapeutics' major shareholders? Top institutional investors of Acrivon Therapeutics include Marshall Wace LLP (1.27%), State Street Corp (0.16%), Empowered Funds LLC (0.13%) and StoneX Group Inc. (0.05%). Insiders that own company stock include Perceptive Advisors Llc, Peter Blume-Jensen, Eric Devroe, Mary Miller, Adam D Levy and Adam D Levy. View institutional ownership trends. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acrivon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Biomea Fusion (BMEA), Archer Aviation (ACHR), Lithium Americas (LAC) and Energy Transfer (ET). Company Calendar Last Earnings11/16/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, ACRV's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACRV CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Price Target for Acrivon Therapeutics$13.50 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+1,073.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.22% Return on Assets-65.85% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book0.32Miscellaneous Outstanding Shares42,850,000Free Float38,403,000Market Cap$49.28 million OptionableNot Optionable Beta1.96 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ACRV) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.